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Abstract 37 
Background: Globally, about 1 billion people have inadequate levels of serum vitamin D and it 38 
appears it is prevalent in all ethnicities and age groups. Few foods naturally contain sufficient 39 
vitamin D; therefore, most people get their requirements through supplementation. Hence vitamin D 40 
status is affected by genetic and environmental determinants including season of measurement, diet 41 
habitual, health status, body mass index and concurrent medication. Further studies are necessary to 42 
understand how genetic variation influences vitamin D metabolism. We aimed to explore the 43 
association between a potential vitamin D-related polymorphism (the rs10766197 polymorphism in 44 
the CYP2R1 gene) with the response to supplementation of vitamin D in 253 healthy Iranian girls. 45 
Material and method: A total of 253 healthy subjects received 50000 IU of vitamin D3 weekly for 46 
9 weeks. Serum 25(OH)D concentrations and metabolic profiles were measured at baseline and after 47 
9 weeks of supplementation. The genotypes of the CYP2R1 variant (rs10766197) were identified 48 
using TaqMan genotyping assays.  49 
Results: Serum 25(OH)D during the supplementation, increased in all individuals. Subjects with a 50 
AA major genotype at this locus had higher vitamin D concentrations after intervention (Changes 51 
(%) 448.4%±425% in AA  vs 382.7%±301% in GG). This genetic variant modulated the response to 52 
supplementation (p <0.001 and p-value SNP=0.05). Regression analysis showed that the probability 53 
of affecting serum 25(OH)D, in individuals who had homozygous major allele GG was two-fold 54 
higher than carriers of the uncommon allele A (OR=2.1 (1-4.2); p = 0.03). Interestingly, the Hs-CRP 55 
was reduced in AA carries while was elevated in individuals with GG and AG genotypes, after high-56 
dose vitamin D supplementation. 57 
Conclusion: Changes in serum vitamin D and metabolic profile following high dose 58 
supplementation with vitamin D were associated with CYP2R1 polymorphism. Although carriers of 59 
the common G allele showed a greater response in the serum vitamin D. 60 
Key words: 25(OH)D, Supplementation, CYP1R2, rs10766197 61 
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Introduction 65 
Diet and other environmental factors such as the intake of vitamin D supplements and exposure to 66 
sunlight are known to influence serum vitamin D concentrations[1]. The assessment of serum 25-67 
hydroxyvitamin D (25(OH)D) is the best biomarker of vitamin D status; however, the optimal serum 68 
concentration is unclear [2, 3]. A study in in the United States, has suggested that a serum 25(OH)D 69 
concentration of 50 nmol/L is sufficient for normal bone health in most individuals [4] whilst other 70 
studies have suggested that 60 nmol/L is necessary for reduction in the risks of falling and fractures 71 
risk [5, 6]. Vitamin D has functions other than bone health.  It is involved in the regulation of more 72 
than 2000 genes. Vitamin D deficiency may be associated with several non-skeletal diseases, 73 
including cancer[7], obesity [8], asthma [9], diabetes [10], cardiovascular diseases (CVD)[11] and 74 
metabolic syndrome (MS) [12] and has been reported as a major public health concern, even in 75 
regions with high levels of sunlight [13], for example it is common in the Middle East, India, Africa, 76 
Australia and South America [14-16].   77 
In line with this, there is increasing evidence for a high prevalence of vitamin D deficiency in Iran; 78 
with reports of deficiency in >80% of the adolescence in Tehran and Arak [17, 18], about 60% of 79 
school-age girls in Yazd [19]  and  >70% in newborn infants in Zanjan [20]. Few foods naturally 80 
contain enough vitamin D , the most natural way to get vitamin D is cutaneous production when skin 81 
is exposed to the sunlight [3]. Public concern about the high prevalence of vitamin D deficiency has 82 
caused increasing demand for supplementation and testing. Since individual responses to 83 
supplementation is variable, a more tailored approach to supplementation may be required. The 84 
variation in serum 25(OH)D level response after supplementation has been attributed to body mass 85 
[21], baseline serum 25(OH)D level [22], supplement dose [23], and the season [22]; however, there 86 
is also convincing evidence that vitamin D status is affected by genotype[24]. Several studies have 87 
reported polymorphisms in candidate genes associated with serum vitamin D that include CYP24A1 88 
and CYP2R1 [25, 26]. Each cytochrome P450 gene is known with CYP, implied that is part of the 89 
cytochrome P450 gene family. The common SNP, rs10766197, located in the promoter region of 90 
CYP2R1 gene, were reliable predictor of serum 25(OH)D levels[27]. 91 
The current study was carried out to examine whether treatment with high dose vitamin D 92 
supplementation is influenced by a variant in the CYP2R1 gene, using data obtained from a 93 
randomized controlled trial of vitamin D supplementation in healthy Iranian school-age girls of 12-94 
18 years old; a group in which vitamin D deficiency is common. 95 
Material and method 96 
Study population 97 
The 253 adolescent girls were recruited between January and April 2015 in Mashhad city, using a 98 
randomized cluster sampling method. Informed consent was collected from all participants using 99 
protocols approved by the Ethics Committee of the Mashhad University of Medical Sciences.  100 
Participants with any chronic diseases history, or who were taking any kinds of dietary supplements 101 
and anti-depressant or psychotropic drugs were excluded from study.  102 
Individuals with history of infectious disease, diabetes mellitus, family history of stroke, and 103 
myocardial infarction were excluded from study. Subjects received 50,000 IU vitamin D/week for 9 104 
weeks. Serum 25(OH)D and metabolic profiles were measured at baseline and after 9 weeks.  105 
Anthropometric and biochemical measurements 106 
Anthropometric parameters (e.g., height, body weight, waist and hip circumference) were measured. 107 
BMI levels among teens expressed relative to other children of the same sex and age. Percentiles 108 
were calculated using CDC growth charts (US Centers for Disease Control and Prevention (CDC) 109 
growth reference), which were based on national survey data collected from 1963-65 to 1988-94 110 
[28]. Biochemical factors including serum serum calcium (Ca),and phosphate (P), , fasting blood 111 
glucose (FBG), creatinie, blood urea nitrogen (BUN)  and lipid profile; total cholesterol (TC), 112 
triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C), measured by using commercial 113 
kits (Pars Azmun, Karaj, Iran) and the BT-3000 auto-analyzer (Biotechnica, Rome, Italy). Low-114 
density lipoprotein cholesterol (LDL-C) was estimated using Friedewald formula if serum TGs 115 
concentrations < 4.52 mmol/L [29-31]. High sensitivity C-reactive protein (Hs-CRP) was quantified 116 
using an immunoturbidimetry method, with limit of detection (LoD) 0.06 mg/L (Biosystems, Spain). 117 
Cut of value for Hs-CRP was < 1.90 mg/L in 5-18 years woman according to 118 
the manufacturer's instructions. 119 
An electrochemiluminescence method (ECL, Roche, Basel, Switzerland) was performed to measure 120 
serum 25-OH vitamin D. The LoD for the 25-OH vitamin D assay was 10 nmol/L for the ECL 121 
(Roche) and intra- and inter-assay variation were 5.7% and 9.9%, respectively.  122 
DNA extraction and genotyping 123 
Genomic DNA was extracted from blood samples using QIAamp® DNA Mini-Kit (Qiagen, San 124 
Diego, CA) according to the manufacturer's instructions. The purity and concentration of DNA 125 
samples were determined using the NanoDrop®-1000-Detector (NanoDrop-Technologies, 126 
Wilmington, USA). Genotype analysis of CYP2R1-rs10766197 polymorphism was carried out using 127 
Taq-man®-probes-based assay; PCR reactions were performed in 12.5 ml total volume, using 20 ng 128 
of DNA in TaqMan®n Universal MasterMix with speciﬁc primers and probes (Applied Biosystems 129 
Foster City, CA). To assess the allelic content. The ABIPRISM-7500 instrument equipped with the 130 
SDS version-2.0 software was used.  131 
Statistics analysis 132 
Data was analyzed using SPSS version 20, IBM (SPSS Inc., IL, USA). Variables are reported as 133 
mean ± standard deviation (SD). Continuous variables were analyzed for normality using the 134 
Kolmogorov–Smirnov test. Analysis of variance (ANOVA) was performed to compare changes in 135 
biomarkers after intervention in different genotype groups. Post hoc analysis was done using 136 
Tukey’s test. A Chi square test with continuity correction was used to determine whether genotype 137 
frequencies followed the Hardy–Weinberg Equilibrium. Repeated measures analysis of covariance 138 
(ANCOVA) was performed to investigate the effect of the genotypes. Logistic regression was 139 
performed to study the probability of change in serum 25(OH)D in the genetic dominant model. 140 
Significance was set at p < 0.05. 141 
Results 142 
Influences of supplementation on circulation 25(OH)D in CYP2R1 variant  143 
In the total population of 253 healthy school-age Iranian girls, 88.1% suffered from vitamin D 144 
deficiency at baseline and only 4% of the total had a desirable vitamin D level. However, after 145 
intervention, 59.7% of the subjects were at a desirable concentration of 25(OH)D. About 20.2% of 146 
the subjects remained vitamin D deficient (Fig. 1). To examine the influence of CYP2R1 variant on 147 
the circulation levels of vitamin D after intervention, subjects were categorized across rs10766197 148 
genotype. The results revealed no significant trend in distribution of vitamin D status (desirable, 149 
sufficiency and deficiency) among different genotypes at baseline (P-trend = 0.4). However, 150 
supplementation for 9 weeks led to significant trend (P-trend =0.05) (Table 1), with a reduction in 151 
the percent of subjects with a low serum vitamin D. The serum 25 (OH) D responses was dependent 152 
on the SNP in CYP1 (Fig. 2). During the supplementation, serum (OH) D increased in all groups, 153 
but carriers who had the common G allele, had higher vitamin D concentrations after 9 weeks of 154 
intervention. The SNP rs10766197 modulated response to vitamin D supplementation (p-value of 155 
intervention effect <0.001 and p-value SNP=0.05) (Fig. 2). Regression analysis also indicated that 156 
the probability of altering serum 25(OH)D, in individuals who had homozygous major allele GG 157 
was two-fold higher than carriers of the uncommon A allele (OR=2.1 (1-4.2); p value=0.03). The 158 
regression model also was significant using a dominant model (OR=1.8 (1-3.1); p value=0.05) 159 
(Table 3). Data was adjusted for potential confounders such as age and BMI percentile.  160 
Influence of supplementation on metabolic profile in CYP2R1 variant 161 
Further analysis showed that fasting blood glucose and triglyceride concentration reduced in all 162 
subjects but carriers of a GG genotype showed a greater reduction in FBG and carriers of AA 163 
genotype showed a greater reduction in serum TG (Table 2). Interestingly, Hs-CRP was also reduced 164 
in AA carriers whilst the individuals with GG and AG genotypes, inflammation increased after 9 165 
week of vitamin D supplementation (Table 2). Change in levels of Ca, BUN, creatinine and P after 166 
supplementation was not statistically significant between different genetic models (Table 2). 167 
Discussion 168 
Influence of supplementation on circulation 25(OH)D in CYP2R1 variant 169 
In the present study, we explored the association of rs10766197 of the CYP2R1 vitamin D-related 170 
gene with serum 25(OH)D concentrations and found that this polymorphism was significantly 171 
associated with the serum 25(OH)D concentrations after 9 weeks of vitamin supplementation and it 172 
appeared that carriers of dominant G allele were better responder to vitamin D in respect to elevation 173 
serum vitamin D. Animal and human studies have shown that different cytochrome P450 enzymes 174 
2(CYP) including CYP2R1, CYP2D25, CYP3A4CYP27A1 are vitamin D 3 25-hydroxylases and 175 
cause 25-hydroxylation of vitamin D 3 and related metabolites[25]. Unlike others 25-hydroxylases, 176 
CYP2R1 hydroxylates both vitamin D 2 and vitamin D 3 [32]. Therefore, genetic variations 177 
including rs10766197, in the promoter region of this gene, may influence 25(OH)D synthesis. Our 178 
data indicated although this genotypic variant was not associated with baseline 25(OH)D level, it 179 
influenced on the response to the supplementation. It is possible that the regulation of 25(OH)D 180 
synthesized by skin might be different from supplementation. In agreement with our study, Nissen et 181 
al. examined variants in some vitamin D-related genes in 201 healthy Danish population. They 182 
reported a significant association between serum 25(OH)D and rs10766197. Similarly, in a study by 183 
Engelman et al. in a female population, all individuals who had no risk alleles of rs4588 and 184 
rs2060793, consuming about 670 IU/d vitamin D, the circulation level of 25(OH)D concentrations 185 
were at sufficient level (> 50 nmol/L). For carriers with 1 and more risk alleles whose intakes were 186 
at least 670 IU/d vitamin D, only more than 50% of subjects had serum 25(OH)D > 50 nmol/L [26]. 187 
Thacher et.al in the cohort study on ricketic Nigerian children, reported that individuals with a 188 
defective CYP2R1 allele had a mild form of VDDR1B and produce less 25(OH)D after intervention 189 
with vitamin D2 or vitamin D3. While, subjects who are homozygous for CYP2R1 mutations showed 190 
a severe form of VDDR1B and had minimal rise in serum 25(OH)D after administration of vitamin 191 
D, and improvement would be only with high doses of vitamin D [25, 33]. In the study of Bu et al. 192 
they found that rs10741657 and rs10766197 were significantly associated with serum 25(OH)D 193 
concentrations in 496 healthy Caucasian people [34]. Based on similar results obtained from several 194 
studies on different population [26, 35, 36] it appeared that variants in the CYP2R1 gene predict 195 
serum 25(OH) D concentrations. 196 
Influence of supplementation on fasted lipid profile and Fasting blood glucose in CYP2R1 variant 197 
We found that, an intake of 50000 IU/D vitamin D per week had beneficial effects not only on 198 
25(OH)D concentrations in all genotype groups but also on glycemic and lipid profile. However, 199 
these effects were greater in the subjects who had GG and AG genotypes at the rs10766197 locus. 200 
Noticeable that although carriers of the uncommon allele A, showed an increase in vitamin D 201 
concentration that was less than for other genotypes, the reduction in TG was more considerable. It 202 
was suggested that vitamin D has both direct and indirect effects on modifying the lipid profile.  203 
An underlying mechanism on improving lipid profile may be through regulatory action of vitamin D 204 
in the simulation of lipoprotein lipase [37] and reduced intestinal absorption and synthesis [38].   205 
Cross-sectional studies have reported a negative relationship between circulation levels of 25(OH) D 206 
and serum Triglyceride. However, the influence of 25(OH) D on TG concentrations in interventional 207 
studies after supplementation with vitamin D is inconsistent [39].  Pittas et al. illustrated that in the 208 
individuals with impaired fasting glucose, administration of vitamin D and calcium might ameliorate 209 
insulin resistance [40].  Jorde et al. in a cross sectional studies examined 8018 non-smoking 210 
individuals, found a significant positive relationship between serum 25(OH)D and serum HDL-C, 211 
TC, and LDL-C and also a significant inverse associations between serum 25(OH)D with both LDL-212 
C/HDL-C ratio and TG [41]. In an interventional study on 438 obese Norwegian, they found no 213 
statistical association between supplementation with vitamin D and lipid profile [42]. Similarly, 214 
Sieda et al. in a meta-analysis showed no significant improvement in glucose parameters[43]. These 215 
controversial illustrations might be partly attributed to the inherent limitations and heterogeneity of 216 
the studied cohorts. Some common factors may be influenced on both the high serum 25(OH)D 217 
levels and favorable lipid profile include exercise, diet habitual and genetic profile.  218 
Influence of supplementation on inflammation in CYP2R1 variant 219 
Our data revealed that inflammation increased in the carriers of dominant allele G after intervention 220 
by vitamin D supplementation while individuals who had AA genotype showed significant reduction 221 
in serum Hs-CRP after supplementation. It appeared that clinical outcome in response to vitamin D 222 
supplementation was genetic-related. Emerging evidence has reported a relationship between 223 
vitamin D supplementation and serum levels of proinflammatory and inflammatory markers such as 224 
cytokines and CRP. Some studies have reported a positive association with circulation levels of 225 
25(OH)D and others showed an inverse association while some declared no relationship [44-47]. 226 
Vitamin D has been shown to suppress in vitro and in vivo the production of proinflammatory 227 
cytokines and modulate both the innate and adaptive immune systems [48, 49]. It is proposed that 228 
macrophages, dendritic cells and activated lymphocytes influence on vitamin D receptor, implying a 229 
crucial role of vitamin D in the immune system [14]. Furthermore, the enzyme 25-hydroxyvitamin is 230 
produced by the immune system [50]. On the other hand, the activated vitamin D down-regulates 231 
proinflammatory mediators, such as interleukin (IL)-6, IL-8 , tumor necrosis factor (TNF) α,  and 232 
monocyte chemoattractant protein (MCP)-1 [51, 52]. However, it is suggested that while 233 
supplementation with vitamin D elevate the 25(OH)D, the conversion of inactive 25(OH)D to active 234 
1,25(OH) D in the kidneys is not immediate, and may not be efficient.  Both the inactive and active 235 
form of vitamin D bind to the vitamin D receptor (VDR), only the 1,25-D allow VDR to perform its 236 
functions beneficially and the 25(OH)D inhibits the VDR functions.  Since VDR is the “gate-237 
keeper” of the innate immune system and modulate by thousand genes so increased levels of 25-D 238 
might show immunosuppressive effects [53].  239 
Generally, discrepancies in the different literature indicate the need for further studies both in 240 
healthy and disease population to find out more details about the potential association between 241 
serum levels of vitamin D and inflammation biomarkers. On the other hand, regulation of serum 242 
vitamin D in human body is a complex process that varies with individual genetic profiles and their 243 
health status. Research in genetic epidemiology of vitamin D is in its infancy and further 244 
comprehensive studies would be needed to understand how genetic variations modulate clinical 245 
outcomes of vitamin D supplementation. 246 
 Conclusion 247 
We have found that although individuals with a GG genotype of CYP2R1 variant had a greater 248 
response to vitamin D supplements, the inflammation status was worsened. However, carriers of AA 249 
genotype showed less increase in 25(OH)D than others, but inflammation status only improved in 250 
this group. We conclude that personalized advice and recommendations tailored to individual’s 251 
genetics seems help to determine how different individuals with various genetic background respond 252 
to the supplementation. People may need different health recommendations based on their genetic 253 
profiles, in order to elevate their serum 25(OH)D concentrations thereby avoiding adverse health 254 
outcomes.  255 
 256 
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Figure 1. Comparison of the vitamin D status before and after 9 weeks of vitamin D 395 
supplementation. Deficiency: Serum 25(OH)D level<50nmol/L. Sufficiency:  50nmol/L<Serum 396 
25(OH)D level<75nmol/L. Desirable>75nmol/L[54]. 397 
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Table 1.  Vitamin D status before and after 9 week of vitamin D supplementation according to CYP2R1 
genotypes. 
Vitamin D status 
(N=253) 
GG (N=72 ) AG (N=119) AA (N=62 ) 
Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Desirable 4 (5.6) 50 (69.4) 2 (1.7) 70 (58.8) 4 (6.5) 31 (50) 
Sufficiency 6 (8.3) 12 (16.7) 10 (8.4) 23 (19.3) 4 (6.5) 16 (25.8) 
deficiency 62 (86.1) 10 (13.9) 107 (89.9) 26 (21.8) 54 (87.1) 15 (24.2) 
Note: Σ2 test showed a Ptrendof 0.4 at baseline; Ptrend at 12-month follow-up is 0.05. Data is presented as 
frequencies (%). Deficiency: Serum 25(OH)D level < 50 nmol/l. Sufficiency: Serum 25(OH) D level between 50 
to 75 nmol/l. Desirable: Serum 25(OH)D level > 75 nmol/l. 
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Table 2.  Comparisons of the variables before and after 9 weeks of vitamin D supplementation in different genetic modes. 
  GG AG AA P value in different genetic models 
 Additive Recessive Dominant 
BMI Percentile 
Baseline 62±56 58.4±28 55.7±26 
Ns Ns Ns Follow-up 56±30 54.6±29 49±27 
Change -17.6±19 -12.4±26.3 -15.9±22.9 
Blood pressure 
SBP (mm Hg) 
Baseline 101±11 100.7±13 99.6±12 
Ns Ns Ns Follow-up 99±13 98.5±13.6 100±12 
Change -1±15.5 -1.2±15 2.1±16 
DBP (mm Hg) Baseline 67±10 67.3±10 67.1±10.5 
Ns Ns Ns 
 
Follow-up 65±11 63±10 64.1±11 
Change -0.5±14 -4.1±12 -2±9.1 
Serum fasted lipids 
Total Cholesterol 
(mg/dL) 
Baseline 164.3±26 165±31 158±28 
Ns Ns Ns Follow-up 150.5±24.5 156±26.5 153±27 
Change -7.4±10.7 -4.6±14.1 -0.1±28 
TG(mg/dL) 
Baseline 87.7±41 79.5±29 83±33 
0.03 Ns 0.03 Follow-up 80.5±40 81±32 70.7±26 
Change -0.8±35.1 4.9±29.6 -7.3±27.1 
HDL(mg/dL) 
Baseline 46.4±8 48.9±9 46.1±8 
Ns Ns Ns Follow-up 44.2±8 46.3±10 44.8±7.5 
Change -3.2±14.1 -2.5±14.5 -1.7±14.3 
LDL(mg/dL) 
Baseline 100.7±20 101.1±27 99.4±21 
Ns Ns Ns Follow-up 89.1±20 92.4±22 93±22 
Change(%) -11.9±17 -9.1±19 -7.1±17.1 
Other blood parameters 
FBG 
Baseline 90±13 88.6±10 86.6±9 
Ns Ns 0.05 Follow-up 87±12 85±12 85.7±10.6 
Change -3±10.8 -4.1±11 -0.9±13.4 
WBC(109/L) 
Baseline 6.3±1.8 6.06±1.6 6.1±1.5 
Ns Ns Ns Follow-up 6.1±1.6 6.1±1.4 5.5±1.3 
Change -1.8±24.6 0.1±27 -4.4±28 
Serum Hs-
CRP(mg/L) 
Baseline 1.3±1.6 1.1±1.1 1.8±1.7 
Ns 0.003 0.05 Follow-up 1.6±2 1.4±1.3 1.1±1.4 
Change 17.7±13 61.6±17.6 -26.8±8.4 
 
25-OH vitamin Baseline 27.5±25 24±18 29±34 (AA vs. 0.049 Ns 
D(nmol/L) Follow-up 99.3±42 86±40 84.4±46 GG) 0.03 
(AA vs. 
AG) 
0.04 
Change 447.3±414.6 423.6±380.4 433.0±426.9 
Ca(mg/dL) 
Baseline 9.6±0.5 9.4±0.5 9.4±0.7 
Ns Ns Ns Follow-up 9.7±0.5 9.7±0.5 9.7±0.5 
Change 0.1±0.6 0.3±0.57 0.3±0.8 
Phosphate(mg/dL) 
Baseline 4±0.5 3.9±0.4 3.9±0.5 
Ns Ns Ns Follow-up 4±0.4 4±0.4 4±0.4 
Change 0±0.4 0.1±0.4 0.1±0.4 
Creatinine(mg/dL) 
Baseline 10.6±3.8 6.6±11.5 5.6±11.8 
Ns Ns Ns Follow-up 0.7±0.09 0.7±0.1 0.7±0.1 
Change 8.7±12.9 10.3±15.2 8.0±13 
BUN(mg/dL) 
Baseline 12.3±3 12.5±3 12.6±3 
Ns Ns Ns Follow-up 13.8±4 13.6±3.2 14±3 
Change 16.3±34.1 15.5±35.3 14.4±30.6 
 Note: Change = ((Follow up – Baseline)/Baseline)/100; p values presented for the changes in different variables after vitamin 
D supplementation according to genotypes; Additive genetic model (GG genotype vs. AG genotype vs. AA genotype); 
Recessive genetic model (GG genotype vs. AG+AA genotypes); Dominant genetic model (GG+AG genotypes vs. AA genotype). 
BMI: body mass index; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; Hs-CRP: high-sensitivity Creative protein; FBG: fasting blood glucose; SBP: systolic blood pressure; 
DBP: diastolic blood pressure; BUN: Blood Urea nitrogen; Ca: Calcium; FBG: Fasting blood glucose.  
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Figure.2.Serum 25(OH)D stratified by a polymorphism in CYP2R1 gene. Values are means ±SD. Two-449 
way ANCOVA repeated measures adjusted for multiple comparisons by Bonferroni test for serum 450 
25(OH)D levels. Covariates used: age, BMI percentile and serum 25(OH)D at baseline. 451 
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Table 3. Association of CPY2R1 variant- rs10766197 with the changes in 
circulation levels of 25(OH)D after 9 weeks of supplementation (under 
different genetic models) 
A
d
d
it
iv
e 
m
o
d
el
 AA AG GG 
Reference  
(Risk group) 
 
OR (CI95%), p value OR (CI95%) 
1 1.6 (0.8-3.3), 0.1 2.1 (1-4.2), 0.03 
R
ec
es
si
ve
 m
o
d
el
 
AG/AG GG 
Reference 
(Risk group) 
OR (CI95%), p value 
1 1.5 (0.9-2.6), 0.1 
D
o
m
in
an
t 
m
o
d
el
 AA AG/GG 
Reference 
(Risk group) 
OR (CI95%), p value 
1 1.8 (1-3-.1), 0.05 
Data was adjusted for age, BMI percentile. 
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